insulin glargine and lixisenatide
| Brand name | Soliqua 100/33 |
|---|---|
| Active ingredient | insulin glargine and lixisenatide |
| Strength | 300UNITS/3ML (100UNITS/ML); 99MCG/3ML (33MCG/ML) |
| Dosage form | Injection |
| Route | Subcutaneous |
| Modality | Biologic |
| FDA approval | November 2016 |
| Marketing status | Rx |
Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.